Loading company…
Zenitar researches and develops medicines for tumors, autoimmune diseases, and other conditions.
Established in 2019 and based in Chengdu, China, Zenitar conducts biopharmaceutical research and development. Its research includes tumors, autoimmune diseases, cytokine storm, B-cell-related tumors, multiple myeloma, polycythemia vera, and essential thrombocythemia. In January 2026, it raised CNY 600 million in Series C funding co-led by Qiming Venture Partners and True Light Capital, with other named investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in